Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) insider Robert Christopher Andrade sold 106,844 shares of the business’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of C$16.63, for a total value of C$1,776,815.72. Following the completion of the sale, the insider directly owned 217,675 shares in the company, valued at C$3,619,935.25. This represents a 32.92% decrease in their position.
Fennec Pharmaceuticals Price Performance
FRX stock remained flat at C$17.00 during midday trading on Friday. Fennec Pharmaceuticals Inc. has a twelve month low of C$7.59 and a twelve month high of C$17.64. The company has a market capitalization of C$596.14 million, a price-to-earnings ratio of -141.67 and a beta of 3.55. The business has a 50 day moving average of C$15.09 and a 200-day moving average of C$12.31.
Institutional Investors Weigh In On Fennec Pharmaceuticals
An institutional investor recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. bought a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned 0.30% of Fennec Pharmaceuticals at the end of the most recent reporting period. 15.23% of the stock is owned by institutional investors.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
See Also
- Five stocks we like better than Fennec Pharmaceuticals
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
